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ABSTRACT: Background: Quality of life in Parkinson’s
disease (PD) is affected by motor and nonmotor symp-
toms, necessitating an integrated care approach. Exis-
ting care models vary considerably in numerous
domains. The objectives of this study were to perform
a systematic review and meta-analysis of PD inte-
grated care models and develop recommendations for
a representative model.
Methods: We conducted a systematic review of publi-
shed integrated care models and a meta-analysis of
randomized, controlled trials examining integrated care
versus standard care. The primary outcome was
health-related quality of life using a validated PD scale.
We evaluated levels of care integration using the Rainbow
Model of Integrated Care.
Results: Forty-eight publications were identified, includ-
ing 8 randomized, controlled trials with health-related
quality of life data (n = 1,149 total PD patients). Qualita-
tive evaluation of individual care model integration
guided by the Rainbow Model of Integrated Care rev-
ealed frequent clinical and professional integration, but
infrequent organizational and population-based integra-
tion elements. Meta-analysis of randomized, controlled
trials revealed significant heterogeneity (I2 = 90%,
P < 0.0001). Subgroup analysis including only outpatient
care models (n = 5) indicated homogeneity of effects
(I2 = 0%, P = 0.52) and improved health-related quality of
life favoring integrated care, with a small effect size
(standardized mean difference [SMD], −0.17; 95% CI,
−0.31 to −0.03; P = 0.02).
Conclusions: Outpatient integrated PD care models
may improve patient-reported health-related quality of
life compared with standard care; however, because
of variable methodological approaches and a high risk
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of bias related to inherent difficulties in study design
(eg, blinding of participants and interventionists), gen-
eralizability of these results are difficult to establish.
The Rainbow Model of Integrated Care is a promising
method of evaluating elements and levels of integra-
tion from individual patient care to population health in
a PD context. © 2020 The Authors. Movement Disor-
ders published by Wiley Periodicals, LLC on behalf of
International Parkinson and Movement Disorder
Society.
Key Words: integrated care; meta-analysis; multi-
disciplinary team; Parkinson’s disease
The treatment of Parkinson’s Disease (PD) remains
limited to symptomatic therapies.1 It is well recognized
that both motor and a wide variety of nonmotor symp-
toms contribute to the overall disease burden in PD,
right from the premotor to the advanced disease stages.
This complexity necessitates an individually tailored,
comprehensive therapeutic approach. This includes
medical management (refined pharmacotherapy, deep
brain stimulation) and nonpharmacological measures
like physiotherapy, occupational therapy, speech ther-
apy, or psychotherapy, as well as education and sup-
port, aiming to improve the health-related quality of
life (HRQoL) of patients and caregivers. Given the het-
erogeneous nature of symptoms across different per-
sons, dedicated care coordinators or PD nurses can
help to achieve the individual therapeutic goals.2
From the perspective of patients, reported core needs
include better information on self-management, sufficient
interdisciplinary collaboration between different health care
professionals, ample time to discuss possible future scenarios,
and an individual health care professional guiding and
supporting them.3 To address these needs, multiple different
integrated care models have been established worldwide,
with widely varying degrees and intensities, but all aiming to
offer PD patients structured and tailor-made comprehensive
care programs. So far, there is limited consistency across
these programs in terms of settings, team composition, or
level of clinical integration. However, most programs do
share certain common disciplines. In addition, results of pub-
lished data have been heterogeneous with respect to study
design and outcomes (including improvement in HRQoL).
There is also variability in the terminology used, with care
models described most commonly as “multidisciplinary,”
“interprofessional,” “interdisciplinary,” or “integrated” (see
information box). Throughout the present article, “inte-
grated care” is the terminology used for consistency, and
proposals regarding terminology as a field moving forward
are also discussed.
To assess these various models and to analyze the
extent of care integration, the Rainbow Model of Care
has been proposed.4 It assesses the degree of care inte-
gration from a health perspective around 4 core
domains (person-centeredness, service coordination,
professional coordination, and organizational coordina-
tion) and 4 ancillary domains (community-centeredness,
functional coordination, normative coordination, and
system integration).4 Our present meta-analysis and
structured review synthesize the available data and evi-
dence about existing integrated care models and their
effects on improvement in the HRQoL of PD patients.
In addition, we analyzed the level of integration of each
model using the Rainbow Model framework. Finally,




This systematic review and meta-analysis assessed the
following specific questions:
1. What are the existing models of integrated care in
PD in terms of the settings, team composition, and
levels of clinical integration?
2. In patients with PD, does provision of integrated
care compared with standard care improve health-
related quality of life, in a health care context that
combined disciplines and/or crossed boundaries of
Information Box: What Is the Right Terminology?64
Intradisciplinary: working within a single
discipline.
Cross-disciplinary: viewing one discipline from the
perspective of another.
Multidisciplinary: people from different disciplines
working together, each drawing on their disciplinary
knowledge.
Interdisciplinary: integrating knowledge and
methods from different disciplines, using a real syn-
thesis of approaches.
Transdisciplinary: creating a unity of intellectual
frameworks beyond the disciplinary perspectives.
Integrated: care approach to strengthen people-
centered health systems through the promotion of
the comprehensive delivery of quality services across
the life course; it is designed according to the multi-
dimensional needs of the population and the individual
and is delivered by a coordinated multi- or interdisci-
plinary team of providers working across settings and
levels of care.
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health care (in-patient, outpatient, primary, second-
ary, or tertiary settings)?
Search
We searched MEDLINE, EMBASE, the Cochrane
Library (Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials
(CENTRAL), and the Web of Science for relevant stud-
ies. The study protocol was submitted to PROSPERO
(CRD42019115444) on December 2, 2018, and regis-
tration was confirmed on January 3, 2019. We
followed the PRISMA reporting guidelines. The search
strategy included terms describing or related to the con-
dition and interventions. The search strategy for
MEDLINE is included in the supplementary informa-
tion. The MEDLINE search strategy was adapted for
use in other electronic databases. Figure 1 presents the
flow chart of the study selection process.
Studies published in the English language or with
English-language translation available were included.
There were no restrictions for inclusion based on geo-
graphical location or year of conducting the study. The
initial search strategy for this review was conducted in
November– December 2018. We repeated the search
strategy in May 2019 and November 2019 to update
the review before publication.
Inclusion/Exclusion Criteria
All studies meeting the following criteria were
included in the review: (1) intervention included inte-
grated care, defined as care involving a movement dis-
orders specialist plus at least 2 other treating providers
based within the center or in the community as part of
the defined integrated care model (clinicians,
Parkinson’s nurses, allied health therapists, or others)
and/or extending beyond the specialist care hospital to
primary care/general neurologist/community/home;
(2) participants included adults (≥18 years) with PD
diagnosed as per United Kingdom Parkinson’s Disease
Society Brain Bank criteria and of either sex; (3) study
setting was either hospital (outpatient or inpatient) or
community based.5 There was no restriction on study
design for studies to be included in the systematic
review. For inclusion in the meta-analysis, additional
criteria were applied: (1) study design was a random-
ized, controlled trial or quasirandomized, controlled
trial; (2) a comparator group was present that received
placebo or standard care; and (3) the study reported
outcomes that included a patient-reported scale for
health-related quality of life validated for use in
PD. Studies spanning inpatient, outpatient, community,
and home settings were included without any geograph-
ical or socioeconomic status restrictions.
Outcomes
For the systematic review, outcomes included iden-
tification of the settings, team composition, compo-
nents of care, and levels of clinical integration
achieved by existing models of integrated care. Fre-
quencies of levels of integration are reported for
included studies regarding the 4 overarching elements
of the Rainbow Model of Integrated Care: clinical
levels of integration (microlevel person-centered care
elements), professional and organizational levels of
integration (mesolevel population-based care), and
system integration (macrolevel population-based
care).6 The presentation of frequencies is qualitative
in nature, and there was no quantitative data analy-
sis comparing the Rainbow Model levels of integra-
tion. For the meta-analysis, the main outcome
parameter was patient-reported health-related qual-
ity of life. The 39-item PDQ-39 questionnaire and a
shortened version, the PDQ-8, are both validated
and widely used measures to assess the quality of life
in PD patients.7-9
FIG. 1. Study flow diagram.
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Data Extraction
Titles and/or abstracts of studies retrieved using the search
strategy were screened independently by 2 review team
members (R.R., L.B.). The full text of studies that meet the
inclusion criteria were retrieved and independently assessed
for eligibility. Disagreements were resolved through discus-
sion with a third reviewer (C.E.). After removal of dupli-
cates, data were extracted from the included studies using a
standardized, prespecified data extraction form. The data
extraction form captured details of the study (author, year of
publication, study design, geographic location), population
(inclusion/exclusion criteria, number of participants, base-
line characteristics), intervention (setting, team composition,
and duration and frequency of intervention), comparator
(if any), levels of integration, outcomes assessed, and infor-
mation for assessment of the risk of bias. The 2 review team
members extracted the data independently, and discrepan-
cies were resolved through discussion mutually and with a
third teammemberwhen required.
Risk of Bias Assessment
Studies included in the meta-analysis were
assessed for internal validity using the Cochrane
risk-of-bias assessment tool. Two review team mem-
bers independently applied the tool for included
studies (R.R., L.B.). Discrepancies were resolved by
mutual discussion.
Data Synthesis and Publication Bias
Assessment
We summarized the data regarding existing models of
interdisciplinary/integrated care in terms of the team
composition, settings, level of integration achieved, and
outcomes monitored/reported. We pooled the results
from randomized, controlled trials that have reported
the same outcome measure (HRQoL) using a random-
effects meta-analysis with standardized mean differences.
We calculated the 95% CI and 2-sided P values for the
outcome measure. Heterogeneity between studies in
effect measures was assessed using the I2 statistic. An I2
value of more than 50% was considered significant het-
erogeneity. RevMan version 5.3 was used to perform the
meta-analysis and generate a funnel plot for visual
inspection of potential publication bias. In addition to
visual/graphic examination of the funnel plot, mathemat-
ical methods for examining publication bias included
those recommended by Begg and Mazumdar, as well as
Egger, Smith, Schneider, and Minder, and were analyzed
using Comprehensive Meta-Analysis version 3.10,11
Rainbow Model of Integrated Care
The Rainbow Model of Integrated Care provides a
validated framework to evaluate the level of integration
of diverse health care models.4 In practice, it defines
4 major domains of integration: clinical, professional,
organizational, and systems integration. The Rainbow
Model specifically identifies practices consistent with
care integration for each domain. For this analysis,
models that explicitly documented at least 1 practice
recommended for care integration in a particular
domain were considered to have achieved care integra-
tion in that domain. Two authors independently graded
the studies for care integration, and discrepancies were
resolved through mutual consensus and an adjudicator
when required.
Results
The combined searches retrieved 2090 records
(Fig. 1). After removal of duplicates and screening of
titles/abstracts, 149 records were chosen for full-text
review. We included 48 records in the qualitative
review, from which 37 studies met the inclusion and
exclusion criteria. The study characteristics of 8 ran-
domized, controlled trials (RCTs) included in the quan-
titative meta-analysis12-19 and 19 other experimental
studies included in the systematic review are presented
in Table 1.20-47 The remaining 10 articles included in
our systematic review were nonexperimental (ie, review
articles or descriptions of care models) and are detailed
separately in Supplementary Table 1.48-57
Systematic Review of Care Models
We identified 37 individual reported models from
48 articles that met our definition of integrated care.
Integrated care practices were reported from varying
locations worldwide (see supplementary materials, Sup-
plementary Fig. 2 for geographical map), although large
parts of the world remained underrepresented. Table 1
presents the characteristics and results of all studies,
including the RCTs included in the meta-analysis, as
well as other studies included in the systematic review
(nonrandomized, controlled trials, pretest/posttest
designs, observational cohort studies, and retrospective
chart reviews).12-47 In the online supplementary mate-
rials, Supplementary Table 1 presents articles with
detailed descriptions of proposed care models and other
related reviews of care models specific to integrated
care in PD.48-57 Core team members included in the
models are shown in Figure 2.
The majority of care models incorporated elements
from 2 broad themes with overlapping features.
Many studies (n = 26) focused on the process of
care coordination including medical and surgical
management, consultations, and allied health
care.12,15,16,27,30,32,33,35,37-43,46,47,49-57 The other major
theme was delivery of multidisciplinary rehabilitation in
various settings (n = 11).13,14,17-19,28,29,34,44,45,48 Among
the care coordination models, 24 were primarily based
1512 Movement Disorders, Vol. 35, No. 9, 2020
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in the outpatient setting with or without care coverage exten-
ding to home or community.12,15,16,27,30,33,35,37-43,47,49-57
Two models were specifically tailored for periopera-
tive evaluation of patients for deep brain stimulation,
and another targeted neuropsychiatric symptoms in a
comprehensive manner.32,39,57 All the other care
models were generic in terms of the health care needs
of persons with PD. One study reported an inpatient
care coordination model specific to PD patients pre-
senting to the emergency department.46 Strategies for
care coordination varied — a majority of the models
involved a point of contact for the patient or care-
giver who functioned as a manager to coordinate
communication and consultations among the patient
and other providers. The primary coordinator role
was taken up by specialist nurses, movement disor-
ders neurologists, or others such as the social
worker.12,14,16,30,33,40-42,46,47,51 This eliminated the
need for the entire care team to be present at a single
site at the same time. Additional telephonic support
and home visits were used across many models to
facilitate this strategy. Team meetings among the
health care providers at frequencies ranging from
daily to monthly were reported as a means of sharing
information among the provider team members. Two
studies reported the use of information technology–based
platforms for the monitoring of patients’ day-to-day
needs, coordination and feedback from the care provider,
one utilized a telehealth solution.53,55,56 Other care coor-
dination models used a ‘one-stop-clinic’ approach, where
care providers from multiple domains met the patient at
the same location over a day or two.35,37-39,49,54 Two
models furthered this approach by taking health care pro-
vider teams to the patient’s home.35,38 Yet another model
of care coordination involved initial management at
expert centers followed by routine care delivery at the
FIG. 2. Composition of teams in models included in the systematic review. The radial bars radiating towards each study represent the team members
in that study. The length of the radial bar represents the frequency at which each profession/ specialty is represented when data is combined across
all studies. For example, PD nurse/ nursing professional (grey bar) was the most common team member across studies, which is represented by the
length of the grey bar. This is followed by movement disorder (MD) specialist (light blue bar), physical therapist (yellow bar) and others. For a more
detailed representation of team composition of an individual model, please see online supplementary material Figure S3. [Color figure can be viewed at
wileyonlinelibrary.com]
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community level through an integrated network of allied
health care professionals.27,50 Multidisciplinary rehabilita-
tion models were either inpatient- (n = 6) or outpatient
(n = 6)–based. Compared with the care coordination
models, the focus of these studies was on multidisciplinary
interventions with physical therapist, occupational thera-
pist, and speech language pathologist playing prominent
roles.
Levels of Integration
Figure 3 illustrates frequencies of individual elements
of each Rainbow Model level of care integration. With
regard to clinical integration (microlevel person-
centered care), all included studies described explicit
consent for proposed care, and the majority of studies
emphasized fostering self-management for PD patients
and providing educational and support opportunities,
whereas the least frequently included element was speci-
fied clinical decision support tools at the point of care.
Standardized processes of service coordination within
institutions was the most common level of professional
integration (population-based care at the mesolevel)
described, whereas multidisciplinary professional edu-
cation opportunities were least frequent. Other ele-
ments extending to population-based care, including
mesolevel organizational integration and macrolevel
systems integration were less frequently achieved,
highlighting challenges for translating individualized




The 8 included RCTs were conducted between 2003
and 2018: 2 in Italy, 2 in the UK, and 1 each in Ger-
many, the United States, Canada, and China.12-19 There
were 1149 participants overall, who were all
community-dwelling adults with PD. Sample sizes of
the individual studies ranged from 44 to 257 persons
living with PD. Mean age of the study participants was
69.4  8.8 years. Mean duration of illness was
7.4  5.8 years as reported in 7 studies.12-14,16-19 Mod-
ified Hoehn & Yahr stage ranged from 1.0 to
4.0.12-15,17
The settings for the intervention were fully inpatient
in 2 studies.13,14 Among the outpatient interventions,
4 were delivered at a specialist center setting with
extension of care to general neurology or home-based
care delivery in 2.16-19 Care delivery was through home
visits alone in 1 study and involved specialist care deliv-
ered in a general neurology setting with extension to
home in one.12,15 All studies delivered the intervention
face to face on an individual basis, with additional
group therapy in 4.12,17-19
Core team members involved in the included studies
are shown in Figure 2. All studies involved a multi-
disciplinary team for intervention delivery. The patient/
caregiver were included for active care delivery in terms
of self-management or monitoring in 4 studies.12,14,16,18
The duration of the intervention program varied from
6 to 32 weeks for the outpatient studies.
Comparison groups involved standard care in all
studies. For 2 studies in which more than 1 multi-
disciplinary intervention was tested, we pooled the data
for the multidisciplinary interventions into a single
intervention group.15,17
All included studies reported measures to assess
HRQoL that are validated or recommended for PD as a
primary or secondary outcome.7 Additional outcomes
reported include Unified Parkinson’s Disease Rating
Scale (UPDRS) items II and III, activities of daily living
(Schwab and England scale, Functional Independence
Measure, Parkinson’s Disease Disability Scale), gait
(Berg Balance Scale, Timed Up and Go test, falls, stand-
walk-sit time), nonmotor symptom assessment scales
(Non Motor Symptoms Scale, Becks Depression
Inventory-2, Parkinson Neuropsychometric Dementia
Assessment, Self-Rating Depression Scale, Montgomery
Asberg Depression Rating Scale, Scales for Outcomes in
Parkinson’s Disease-Psychosocial, Hospital Anxiety
Depression Scale), medication dosages (levodopa-
equivalent daily dose), hospital admissions, patient sat-
isfaction, and caregiver strain (Caregiver Strain Index).
One study reported costs analysis.15 None of the
included studies reported adherence to care quality
measures. Adverse events were documented in 2 studies
— one reported no adverse events and the other minor
adverse events (transient pain, mood disturbances,
autonomic, and sensory problems), which were similar
in frequency in both the intervention and control
groups.14,17 No major adverse events were reported.
Risk of Bias in Included Studies
The risk of bias assessment for included studies is
presented in the supplementary materials
(Supplementary Fig. 1a,b). The trials covered a wide
range of methodological quality and no study achieved
low risk in all the seven criteria assessed. Specifically,
high risk of performance bias was common to all the
studies because of practical issues associated with
blinding of participants and personnel. Analysis for the
presence of possible publication bias was mixed. The
Begg and Mazumdar rank correlation test was not sig-
nificant (P = 0.13, 1-tailed); however, visual inspection
of the funnel plot was asymmetric (Supplementary
Fig. 1c), and Egger’s regression intercept test was signif-
icant (P = 0.01, 1-tailed), suggesting the presence of
publication bias in this literature.
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Effects of Interventions — Quality of Life
HRQoL scores were available for 1149 participants.
HRQoL measures used were PDQ-39 (n = 7) and
PDQ-8 (n = 1). We used a stepwise approach for the
meta-analysis. Pooling data from all the available RCTs
(n = 8) resulted in significant heterogeneity (I2 = 90%).
Various factors including the intervention that was
delivered, setting, duration of follow-up and quality of
the studies were considered to be contributing to the
heterogeneity. One single study that reported a short-
FIG. 3. Rainbow model levels of integration. [Color figure can be viewed at wileyonlinelibrary.com]
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term outcome (assessment at the end of 8 weeks of
intervention) showed a significant effect in favor of
integrated care (SMD, −4.10; 95% CI, −5.17 to −3.02;
P < 0.001).18 Although this study contributed only
7.6% to the overall results in terms of weight, we per-
formed a sensitivity analysis excluding it. In this model,
we pooled data from the remaining 7 studies that
reported long-term outcomes (at least 6 months), that
did not alter the results and still revealed significant het-
erogeneity (I2 = 74%). This model included studies of
integrated care delivered both in the outpatient and the
inpatient settings. The patient population in the inpa-
tient studies was significantly older than in the outpa-
tient studies, and the intensity and frequency of
intervention was different among these groups. Consid-
ering the heterogeneity in the population and interven-
tion, we performed a post hoc exploratory subgroup
analysis pooling data from studies assessing outpatient
integrated care models separately (Fig. 4). Heterogene-
ity using the I2 statistic was 0% for this subgroup.
Pooled data from the outpatient programs reporting
long-term outcome suggested a significant effect of inte-
grated care on quality of life in PD compared with stan-
dard care (SMD, −0.17; 95% CI, −0.31 to −0.03;
P = 0.02). A single study that reported short-term out-
come (8 weeks) in the outpatient setting showed a sig-
nificant effect in favor of integrated care (SMD, −4.10;
95% CI, −5.17 to −3.02; P < 0.001).18 Significant het-
erogeneity (I2 = 92%) limited the interpretation of
pooled results from the 2 studies done in an inpatient
setting.13,14
Discussion
This systematic review identified several unique
models of health care offering multidisciplinary and
integrated care to patients with PD. We identified
models operating across inpatient hospital care, outpa-
tient hospital care, and community-based settings. Most
models achieved clinical integration as assessed by the
Rainbow Model of Integrated Care; however, the
highest level of care integration, systems integration,
was achieved by only a few models.18,27,35,37,50,54
Although integrated care models were reported from a
number of geographic locations, there were limited data
available from large parts of the world, particularly
Asia and Africa. We performed a meta-analysis to iden-
tify the effects of integrated care on health-related qual-
ity of life, which is an important patient-reported
outcome that reflects the holistic effects of an interven-
tion on physical, mental, and social domains. When
considering the interventions overall, significant hetero-
geneity limited pooling of data across studies. In addi-
tion to the variability of interventions delivered,
differences in the population, geographic setting, and
timing of outcome assessment could contribute to the
observed heterogeneity. Hence, we performed an
exploratory subgroup analysis combining interventions
delivered in the outpatient and inpatient settings and
reporting short-term and longer-term outcomes sepa-
rately. The meta-analysis of pooled data from random-
ized, controlled trials identified a modest yet significant
favorable effect of outpatient-based integrated care on
quality of life compared with usual care, without signif-
icant heterogeneity.
Many Models Available — But Are They
Comparable?
This work demonstrates substantial variety in inte-
grated care approaches with varying levels of care inte-
gration in PD. Although our subgroup analysis revealed
no statistical heterogeneity for the HRQoL outcome, it
is questionable whether these individual models are
really comparable and whether the outcome data are
truly combinable. We asked whether integrated care as
an entity affected HRQoL and prespecified a definition
of integrated care. Although the individual components
and settings may vary across different models, they all
meet the core definition of integrated care. Further data
from head-to-head comparisons may be required to
understand the strengths and weaknesses of the various
individual models. However, previous studies in other
fields such as chronic pulmonary disease, cancer care,
and chronic kidney disease have successfully assessed
the effect of multidisciplinary and integrated care using
similar techniques, despite individual variations in
FIG. 4. Forest plot of meta-analysis exploratory subgroup analysis. Forest plot of data from studies assessing the effect of integrated care delivered in
the out-patient setting on Health Related Quality of Life at six months or beyond, compared to standard care showing significant effect in favor of inte-
grated care (SMD −0.17 [−0.31 - −0.03], I2 = 0%). [Color figure can be viewed at wileyonlinelibrary.com]
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models.58-61 As the primary outcome parameter for
HRQoL reported in all RCTs was homogenous, we
could combine the outcomes. Although the effect size
was modest, the strongest improvements in HRQoL
were seen in outpatient settings, which reflect the
nature of integrated care as a model for chronic dis-
eases that takes place mainly in outpatient settings.
These results emphasize the role of integrated care in
care coordination and care management rather than
solely the effects of distinct therapeutic approaches (eg,
physiotherapy or speech therapy only). It is also impor-
tant to note that individual components of each care
model included in the present review are interventions
that are commonly used in isolation rather than specifi-
cally developed for integrated care programs. Although
types of individual interventions included in respective
models are variable and no 2 care models were identi-
cal, we defined each as “integrated care” according to
specific criteria in an effort to conduct a quantitative
analysis, as well as evaluate care models using the Rain-
bow Model.
Comparing these models in a clinical trial environ-
ment reveals the difficulties in conducting this type of
study: many variables cannot be thoroughly controlled.
This hampers the assessment of multifaceted interven-
tions. Blinding the participants and intervention pro-
viders is another major challenge in practice and may
contribute to significant bias, especially when using
patient-reported outcomes. Subject attrition and
cointerventions may also be higher with nonblinded
study designs.62 Most of the included studies did not
report how they dealt with this potential bias. How-
ever, so far, no solution has been developed to control
for the various varying and influencing factors in a
complex model of care.
We decided to use the most often chosen primary
outcome (namely, HRQoL) for further assessment and
comparison of the various models. We acknowledge
that this outcome alone might not reflect the best effi-
cacy of a multifaceted intervention. There could be
other informative outcomes such as measures rec-
ommended by the World Health Organization (WHO)
to assess functionality, health, and disability, for exam-
ple, the WHO Disability Assessment Schedule, a generic
assessment instrument for health and disability across
all diseases, including neurological disorders or a Likert
scale self-reported global rating of well-being.63 Cur-
rently, only a very few studies in PD use these tools as
outcomes. Probably, selection of outcomes based on the
conceptual framework of the International Classifica-
tion of Functionality in future studies may enlarge the
evidence in integrated care models. However, these out-
comes were inconsistently reported in the published
studies, precluding their use for a meta-analysis.
One solution to assess the extent of integrated care
could be the Rainbow Model of Integrated Care
Measurement Tool (RMIC-MT), which allows for mea-
surement of the degree of integrated care from a health
professional and managers’ perspective.64 Patient-
perceived care coordination is assessed through a con-
sumer version of the RMIC-MT.65 The RMIC-MT
could be used as a future tool for outcome assessment
of integrated care models.
Another point to consider here is the global variabil-
ity: most models are developed and adopted according
to local/regional conditions and requirements. There is
not a “one-size-fits-all” approach that has been devel-
oped up to this point, which makes results heteroge-
neous and comparability complex. Learning from this
variability can be driven through scenarios for, for
example, Delphi panels, to identify the crucial team
members to deliver integrated care. It is not only the
heterogeneity of models but also the different interpre-
tations or inconsistencies in terminology that adds to
the difficulties in developing a unified approach.66
These definitions focus on team aspects, whereas the
term integrated care sets the patient at the center. After
thorough reflection within the task force and a search
for definitions, we decided to use the term integrated
care throughout this article, as we considered this the
most appropriate wording to describe a care approach
to strengthen people-centered health systems through
the promotion of the comprehensive delivery of quality
services across the life span. Integrated care is designed
according to the multidimensional needs of the popula-
tion and the individual and is delivered by a coordi-
nated multi- or interdisciplinary team of providers
working across settings and levels of care. This defini-
tion follows the World Health Organization and
describes the ultimate aim of the best possible integra-
tion of a model into an existing health care system.67
We are aware that this definition does not fully reflect
many of the applied models; however, we propose that
the term integrated care should be used in the future to
describe models of coordinated and interdisciplinary
care for PD patients (and caregivers).
What Has to Be Considered to Deliver Future
Integrated Care in PD?
Despite many open questions, there are already some
key findings that could be considered for the implemen-
tation of current or future integrated care models in
PD. A recent practice-based evidence approach has
suggested some major recommendations for the organi-
zation of integrated clinical care teams in PD (Radder
et al, submitted). Furthermore, there are some team
members who have not been identified as “classic” can-
didates of an integrated care model for PD, for example,
the specialist in vascular medicine, gastroenterologist,
pulmonologist, neuro-ophthalmologist, urologist, geria-
trician/elderly care physician, palliative care specialist,
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and the dentist. The inclusion of these specialties might
increase awareness about the complexity of PD-
associated nonmotor symptoms and lead to initiation of
more efficient referrals to the appropriate health care
professionals.68 Indeed, a recent RCT showed extended
multidisciplinary care to be better than standard multi-
disciplinary rehabilitation in PD.45
With further evolution of digital infrastructures, inte-
grated care models have the large potential to harmo-
nize health care pathways, personalize health care
utilization according to individual needs, and facilitate
communication between health care providers.69 How-
ever, systematic data on these emerging techniques and
applications are currently limited.
As researchers continue to work toward discovery of
disease-modifying strategies to slow down, halt, or even
reverse the neurodegenerative process associated with
PD, it is important to highlight that the primary goals
of integrated care models may shift in the future. At
such time, when significant strides have been realized in
this realm and some form of disease modification has
actually become available, the composition of team
members and overall structure of integrated care pro-
grams might have to be revisited.
Strength and Weaknesses of the Methodology
Using the term parkinsonism is open to the question
of whether Parkinson;s disease or atypical parkinsonian
syndromes (APS) are included in a trial, and if PD or
APS patients are adequately included.70 Two non-RCTs
included in the systematic review included PD and APS
patients, although the large majority in both studies
(79% or more) of the total sample comprised PD
patients.35,37 Broadly, if integrated care models intend
to emphasize individual person-centered assessment
and care, including all parkinsonian syndromes, is logi-
cal, as the assessments and treatments will be tailored
to their needs. However, from an analytic perspective,
in future trials, it is recommended that subgroup analy-
sis of PD patients be performed, as well as atypical syn-
drome subgroup analysis if sample size allows.
There is a growing body of evidence over the past
decades that sex-specific issues have a larger impact on
women with PD. Female sex is independently associ-
ated with more nonmotor symptoms and a poorer
HRQoL in PD.71 Women assess severity and burden of
the disease differently.72,73 Furthermore, the therapeutic
access for women is different, for example, women are
less likely to undergo deep brain stimulation.74 Just
recently it has been brought to the discussion that
women with PD are underrepresented in clinical trials,
with a skew of more than 7% male PD patients.75
These findings could not be confirmed because of a lack
of specific data in the RCTs. Future trials should
incorporate data on sex diversity to address sex-specific
issues accordingly.
In evaluating the 8 RCTs included in the overall
meta-analysis, although the methodological strength of
using a randomized, controlled design across the indi-
vidual studies is favorable for a higher degree of cer-
tainty, no study achieved low risk in all the criteria of
risk of bias assessment. In addition, all were judged to
be at high risk of performance bias related to practical
difficulties associated with blinding of participants and
intervention personnel. On an individual study level as
well as in our meta-analytic results, we thus grade the
level of certainty according to the GRADE framework
to be very low.
As previously noted, there are no solutions to control
for the inherent variability and influencing factors in a
complex integrated care model. In addition, integrated
care models aim to tailor interventions depending on
the assessment of specific patient needs and team mem-
ber communication in an effort to individualize treat-
ment plans. Because of the inherent variability in
aspects of care models, considerable resources required
to develop and implement integrated care models, and
the vital inclusion of shared decision-making processes
among patients and team members providing interven-
tions to personalize care, recommendations for inte-
grated care models — including our own — will qualify
as “weak” according to GRADE criteria. Thus,
although our conclusions suggest a possible positive
effect of integrated care on quality of life in PD, this
should be further studied in trials if methods are pro-
posed and developed in the future to control for the
myriad influencing factors in an integrated and com-
plex model of care. Overcoming these methodological
challenges may improve the certainty of evidence and
strength of recommendations.
Considerations for Future Integrated Care
Trials
Despite the large variety of existing studies and the
various approaches of integrated care projects, several
recommendations for future integrated care trials can
be derived. First, a controlled study design including
blinding of patients and health care professionals is a
major precondition for any future RCT. However,
because of the multicomponent intervention designs,
including several nonpharmacological interventions in
which the blinding of health care providers is not possi-
ble, guarantee of a true double-blinding of conditions is
challenging. One partial solution can be a cluster ran-
domization design, which has been used successfully
before to evaluate complex care interventions in PD.76
Second, a true placebo-design is hardly achievable.
Thus, a head-to-head design, comparing the standard
of care with a new intervention design is the most
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favorable approach. Third, the inclusion of detailed
description of the interventions, level and strategy of
integration among the disciplines and health services is
fundamental to facilitating the study’s reproducibility
and comparison of results. Fourth, researchers and cli-
nicians should be encouraged to install new integrated
care models incorporating elements of a clinical trial
design as much as feasible when installing new inte-
grated care outfits to enlarge knowledge about the
effectiveness of integrated care models and the factors
that promote optimal outcomes.
After analysis of the existing data, we recommend for
future trials to incorporate details about: (1) the inte-
gration level among the professionals (shared evalua-
tions/purposes/interventions), (2) the level of patient
empowerment (education, shared decision making),
(3) the level of expertise of professionals, (4) frequency
and duration of each intervention, (5) the model for
integration of the crossed boundaries of health care,
and (6) the level of patients’ education. Additional rec-
ommendations for future studies include evaluation of
cost-effectiveness and feasibility within the respective
health care system and country, identification of indi-
vidual components of care models yielding the largest
improvements in outcomes, and how to implement best
practice in the broadest sense achievable (eg, in regions
or settings where resources may be limited). Few studies
report comprehensive costs of delivering integrated
care, including implementation and maintenance costs,
as well as additional costly outcomes such as hospital
admissions, emergency service utilization, and others.
Future studies should assess these for diverse settings
and different models to understand the impact of inte-
grated care on actual costs. Apart from the economic
impact, challenges in delivering integrated care vary in
different health care settings. Integrating such care
models into existing health care frameworks may
require reforms at organizational levels. Communica-
tion between team members is a vital component of
integrated care and may require targeted solutions.
Above all, maintaining the patient-centeredness of any
care model requires an ongoing feedback and modifica-
tion mechanism in which the patient and caregiver play
equally vital roles.
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